Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Glen Weiss, MD
Cogent Biosciences, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Yale Smilow Cancer Hospital
New Haven, Connecticut, United States
- Miami University Cancer Center
Miami, Florida, United States
- the Ohio State University
Columbus, Ohio, United States
- Sarah Cannon Research Institute/tennessee Oncology, Pllc
Nashville, Tennessee, United States
- Baylor Scott & White Medical Center
Dallas, Texas, United States
- Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Mar 2019
- Primary completion
- 12 Mar 2020
- Completion
- 12 Mar 2020
- Last update posted
- 31 Mar 2020
- Registered enrollment
- 6
- Registry id
- NCT03680560
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.